Home/Filings/4/0001431373-11-000006
4//SEC Filing

Wilkinson Michael O. 4

Accession 0001431373-11-000006

CIK 0001003124other

Filed

Dec 5, 7:00 PM ET

Accepted

Dec 6, 9:16 AM ET

Size

25.7 KB

Accession

0001431373-11-000006

Insider Transaction Report

Form 4
Period: 2011-12-05
Wilkinson Michael O.
Executive Vice President
Transactions
  • Discretionary Transaction

    Common Stock

    2011-11-22$24.98/sh+280$6,9942,362 total
  • Disposition to Issuer

    Stock Options (to buy)

    2011-12-0521,0520 total
    Exercise: $20.45Common Stock (21,052 underlying)
  • Disposition to Issuer

    Stock Options (to buy)

    2011-12-0518,6320 total
    Exercise: $37.69Common Stock (18,632 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2011-12-0510,0000 total
    Common Stock (10,000 underlying)
  • Disposition to Issuer

    Stock Options (to buy)

    2011-12-0512,4850 total
    Exercise: $25.74Common Stock (12,485 underlying)
  • Disposition to Issuer

    Stock Options (to buy)

    2011-12-0515,0000 total
    Exercise: $26.64Common Stock (15,000 underlying)
  • Disposition to Issuer

    Stock Options (to buy)

    2011-12-0562,1040 total
    Exercise: $33.80Common Stock (62,104 underlying)
  • Disposition to Issuer

    Stock Options (to buy)

    2011-12-056,2110 total
    Exercise: $19.94Common Stock (6,211 underlying)
  • Disposition to Issuer

    Stock Options (to buy)

    2011-12-057,7630 total
    Exercise: $43.26Common Stock (7,763 underlying)
  • Disposition to Issuer

    Common Stock

    2011-12-05$33.25/sh2,362$78,5370 total
Footnotes (7)
  • [F1]Includes shares acquired under the automatic dividend reinvestment provision of the Company's Employee Stock Purchase Plan.
  • [F2]Pursuant to the Agreement and Plan of Merger (the "Agreement") by and among Pharmaceutical Product Development, Inc., Jaguar Holdings, LLC and Jaguar Merger Sub, Inc. dated as of October 2, 2011, on the effective date of the merger contemplated by the Agreement (the "Merger"), each of these shares of common stock was automatically converted into the right to receive $33.25.
  • [F3]These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference (if any) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes. The options were scheduled to vest in three equal increments on 2/18/10, 2/18/11 and 2/18/12 but vesting was accelerated due to the Merger.
  • [F4]These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference (if any) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes. The options were scheduled to vest in three equal increments on 2/25/11, 2/25/12 and 2/25/13 but vesting was accelerated due to the Merger.
  • [F5]These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference (if any) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes. The options were scheduled to vest in three equal increments on 6/17/11, 6/17/12 and 6/17/13 but vesting was accelerated due to the Merger.
  • [F6]These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference (if any) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes.
  • [F7]Each restricted stock unit (RSU) represents a contingent right to receive one share of PPDI common stock. The RSUs were scheduled to vest in three equal increments on 2/23/12, 2/23/13 and 2/23/14 but became fully vested pursuant to the terms of the Agreement. The RSUs were disposed of pursuant to the terms of the Agreement in exchange for a cash payment of $33.25 per share upon the effective date of the Merger.

Issuer

PHARMACEUTICAL PRODUCT DEVELOPMENT INC

CIK 0001003124

Entity typeother

Related Parties

1
  • filerCIK 0001431373

Filing Metadata

Form type
4
Filed
Dec 5, 7:00 PM ET
Accepted
Dec 6, 9:16 AM ET
Size
25.7 KB